REBYOTA™ Prospective Registry
(ROAR Trial)
Trial Summary
What is the purpose of this trial?
This trial collects data on patients who received REBYOTA™ to prevent repeated gut infections. It targets those with recurrent Clostridioides difficile infections and works by restoring healthy bacteria in the intestines. REBYOTA™ is used to restore healthy bacteria in the intestines, with cure rates of about 87% in treating recurrent Clostridioides difficile infections.
Research Team
Global Clinical Compliance
Principal Investigator
Ferring Pharmaceuticals
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive REBYOTA™ for the prevention of recurrent Clostridioides Difficile Infection (rCDI)
Follow-up
Data about clinical history, CDI events, symptoms, treatments, medical procedures, Adverse Events, and healthcare resource utilization are collected through 6 months of follow-up
Treatment Details
Interventions
- REBYOTA™
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ferring Pharmaceuticals
Lead Sponsor
Pierre-Yves Berclaz
Ferring Pharmaceuticals
Chief Medical Officer since 2023
MD from the University of Lausanne, PhD in Molecular Biology from the Cincinnati College of Medicine
Jean-Frédéric Paulsen
Ferring Pharmaceuticals
Chief Executive Officer since 2023
Master’s degree in Finance from the London School of Economics and Political Science